Overview

Fasiglifam 25 mg BID vs 50 mg QD

Status:
Terminated

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda